AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
Trump’s pharmaceutical tariffs could affect some drugmakers more than others
Related Posts
China to impose retaliatory tariffs on some Canadian products as trade war heats up
China on Saturday announced retaliatory tariffs on Canadian agricultural goods, hitting back after Ottawa slapped import duties on Chinese-made EVs.
MassiveDS: A 1.4 Trillion-Token Datastore Enabling Language Models to Achieve Superior Efficiency and Accuracy in Knowledge-Intensive NLP Applications
Language models have become a cornerstone of modern NLP, enabling significant advancements in various applications, including text generation, machine translation,…
Zelensky says no peace deal without Ukraine involvement
Ukraine’s president says he will not be shut out of peace negotiations after Trump says he agreed to start talks…